CD40-activated B cells induce anti-tumor immunity in vivo

The introduction of checkpoint inhibitors represents a major advance in cancer immunotherapy. Some studies on checkpoint inhibition demonstrate that combinatorial immunotherapies with secondary drivers of anti-tumor immunity provide beneficial effects for patients that do not show a strong endogenou...

Descripción completa

Detalles Bibliográficos
Autores principales: Wennhold, Kerstin, Weber, Tanja M., Klein-Gonzalez, Nela, Thelen, Martin, Garcia-Marquez, Maria, Chakupurakal, Geothy, Fiedler, Anne, Schlösser, Hans A., Fischer, Rieke, Theurich, Sebastian, Shimabukuro-Vornhagen, Alexander, von Bergwelt-Baildon, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438605/
https://www.ncbi.nlm.nih.gov/pubmed/26934557
http://dx.doi.org/10.18632/oncotarget.7720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438605/
https://www.ncbi.nlm.nih.gov/pubmed/26934557
http://dx.doi.org/10.18632/oncotarget.7720

Ejemplares similares